Teva Pharmaceutical Industries Limited (TEVA) Fair Value 2026

TEVA · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-28, Teva Pharmaceutical Industries Limited (TEVA) trades at $36.44, versus a $20.69 median fair value across its 11 active models — 43.2% below the current price. QOC: 6.7/10. Value Trap Risk: 33/100 (LOW). 11/13 models active. Within that set, the Bayesian DCF component alone returns $29.70.

Key Facts

Ticker
TEVA
Price
$36.44
Quality Score
6.7/10
Value Trap Risk
33/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +43.7% upside with 67% confidence
Risk: Majority of models suggest overvaluation

Is Teva Pharmaceutical Industries Limited (TEVA) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Teva Pharmaceutical Industries Limited (TEVA) appears overvalued as of : the median of 11 independent fair value estimates is $20.69, 43.2% below the current price of $36.44. Estimates range from $4.44 to $60.73. TEVA scores 6.7/10 on fundamental quality and 33/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. TEVA’s -43.2% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Teva Pharmaceutical Industries Limited Stock in 2026? →

What Fair Value Does Each Model Give TEVA?

11 Intrinsic Value Models vs. Current Price ($36.44)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $29.70 -18.5%
Ensemble · Low Conviction
 $26.26 -27.9%
Scenario · High Conviction
 $52.36 +43.7%
Intrinsic · High Conviction
 $4.44 -87.8%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is TEVA's Fair Value Range?

Spread across 11 independent models · $4.44 to $60.73

CirclFi's 11 active models place Teva Pharmaceutical Industries Limited (TEVA) between $4.44 and $60.73 per share, a spread of 272% of the median. The median of that range — $20.69 — is the fair value CirclFi publishes for TEVA, against a current price of $36.44.

Low · ML-RIVHigh · Regime Cross
$4.44median $20.69$60.73
Where the range comes from
Most bearish modelML Residual Income$4.44
Most bullish modelRegime Cross-Sectional$60.73
Model agreement3 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TEVA. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TEVA, not a CirclFi price target. How each model works →

What Is Teva Pharmaceutical Industries Limited (TEVA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Teva Pharmaceutical Industries Limited's intrinsic value is estimated at a median fair value of $20.69. Trading at $36.44, the stock is approaching fair value or slight overvaluation (implied return of -43.2%), as 8 of 11 models suggest limited further upside. Notably, Regime Cross sees the most upside at +66.7% (fair value: $60.73), while ML-RIV is the most conservative at -87.8% ($4.44). The spread between these extremes — +154.5% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About TEVA?

11 of 13 models are currently active for TEVA. Of these, 3 models suggest upside while 8 models suggest overvaluation. Taken together, their median fair value for TEVA is $20.69 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $29.70 on its own, implying -18.5% downside from the current price. See which stocks rank higher →

How Does TEVA Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, TEVA ranks #37 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Teva Pharmaceutical Industries Limited's positioning within the Drug Manufacturers - Specialty & Generic segment means that revenue per drug plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.

Is TEVA a Value Trap?

CirclFi's Value Trap algorithm assigns TEVA a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Teva Pharmaceutical Industries Limited. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Teva Pharmaceutical Industries Limited earns a quality score of 6.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +154.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TEVA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TEVA's 11 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Teva Pharmaceutical Industries Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

ANIKAnika Therapeutics, Inc.QOC 6.8AKBAAkebia Therapeutics, Inc.QOC 6.6MRMDMariMed Inc.QOC 6.8ADCTADC Therapeutics SAQOC 6.5BHCBausch Health Companies Inc.QOC 6.8ACBAurora Cannabis Inc.QOC 6.5TKNOAlpha Teknova, Inc.QOC 5.8STEKStemtech CorporationQOC 4.5COLLCollegium Pharmaceutical, Inc.QOC 8.8UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: ANIK · AKBA · MRMD · ADCT · BHC · ACB · TKNO · STEK · COLL · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to TEVA?

7 companies across all industries closest to TEVA’s Quality of Company score of 6.7/10.

LTCHLatch, Inc.QOC 6.7BCYCBicycle Therapeutics plcQOC 6.7PRPOPrecipio, Inc.QOC 6.7LEGNLegend Biotech CorporationQOC 6.7SWAGStran & Company, Inc.QOC 6.7VNOMViper Energy, Inc.QOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LTCH · BCYC · PRPO · LEGN · SWAG · VNOM · NVDA

Where Does TEVA Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

TEVA is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Teva Pharmaceutical Industries Limited’s Valuation?

What is Teva Pharmaceutical Industries Limited's intrinsic value in 2026?

CirclFi puts Teva Pharmaceutical Industries Limited (TEVA)'s intrinsic value at $20.69 — the median of 11 independent model estimates as of 2026-08-28, ranging from $4.44 to $60.73. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $29.70 on its own. The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TEVA overvalued or undervalued right now?

At $36.44, 3 of 11 active models suggest TEVA may be undervalued, while 8 indicate potential overvaluation. The median of all 11 fair value estimates is $20.69, 43.2% below the current price of $36.44 — a consensus view that TEVA is overvalued. The assessment depends on which methodology best fits Teva Pharmaceutical Industries Limited's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.7 mean for TEVA?

Teva Pharmaceutical Industries Limited's QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TEVA?

CirclFi analyzes TEVA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TEVA?

Of the 11 models currently active on TEVA, Regime Cross-Sectional is the most bullish at $60.73 per share, and ML Residual Income is the most bearish at $4.44. CirclFi's published fair value for TEVA is the median of that range, $20.69, not either extreme. The gap between the two ends equals 272% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TEVA a value trap in 2026?

Teva Pharmaceutical Industries Limited's Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Teva Pharmaceutical Industries Limited (TEVA) has a median fair value of $20.69 — 43.2% below the current price of $36.44 — as of 2026-08-28.” Source: circlfi.com/stock/TEVA/ · Methodology
Primary sources for this TEVA valuation

Market data for TEVA as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on TEVA.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for TEVA Unlock All 11 — $39/mo